Segments Covered in This Report By Mechanism of Action GLP-1 Receptor Agonists Dual GIP/GLP-1 Agonists Triple or Multi-Receptor Agonists Centrally Acting Sympathomimetics Peripherally Acting Lipase Inhibitors By Drug Type Prescription Drugs OTC Drugs By Route of Administration Injectable (Weekly / Monthly) Oral Daily Pills By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies & Tele-health Platforms Weight-Loss Clinics Geography North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific China Japan India South Korea Australia Rest of Asia-Pacific Middle East and Africa GCC South Africa Rest of Middle East and Africa South America Brazil Argentina Rest of South America Data Sources, Market Sizing, and Validation Primary Research Endocrinologists, payers, pharmacists, and supply-chain executives across North America, Europe, Asia-Pacific, and the Gulf were interviewed to confirm real-world adherence, mark-ups, and production ramp-ups
Norma Frahn, who operates two businesses On Demand HR Solutions, an HR consultancy, and Mind Body Plate, a coaching practice focused on helping people with food and weight issues has witnessed this transformation firsthand
However, most GLP-1s for weight loss are not fully covered unless they are prescribed for diabetes
Initial consultation Medication Shipping Injection supplies (where applicable) App-based support (messaging, dosage guidance, and educational resources such as protein targets and sleep content) Whats Missing
